-

Alto Neuroscience to Participate in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June:

  • Jefferies Global Healthcare Conference, June 3-5th 2025:
    • Format: Fireside chat and one-on-one investor meetings
    • Presentation Date/Time: Thursday, June 5, 2025, at 2:00 pm ET
    • Location: New York Marriott Marquis
  • H.C. Wainwright 6th Annual Neuro Perspectives Conference, June 16-17th 2025:
    • Format: Fireside chat and one-on-one investor meetings
    • Presentation available on-demand beginning: Tuesday, June 17, 2025, at 7:00 am ET

Available presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

Contacts

Investor Contact:
Nick Smith
investors@altoneuroscience.com

Media Contact:
Mari Purpura
media@altoneuroscience.com

Alto Neuroscience, Inc.

NYSE:ANRO

Release Versions
$Cashtags

Contacts

Investor Contact:
Nick Smith
investors@altoneuroscience.com

Media Contact:
Mari Purpura
media@altoneuroscience.com

Social Media Profiles
More News From Alto Neuroscience, Inc.

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the...

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience’s leadership team, Patricio O’Donn...

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effec...
Back to Newsroom